100763-71-1

Basic information

• Product Name: 2-amino-4-phenoxy-6-chloropyrimidine
• Synonyms: 2-amino-4-phenoxy-6-chloropyrimidine
• CAS NO: 100763-71-1
• Molecular Formula: C₁₀H₈ClN₃O
• Molecular Weight: 222
• Mol File: 100763-71-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-amino-4-phenoxy-6-chloropyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4-phenoxy-6-chloropyrimidine(100763-71-1)
• EPA Substance Registry System: 2-amino-4-phenoxy-6-chloropyrimidine(100763-71-1)

Safety Data

• Hazardous Substances Data: 100763-71-1(Hazardous Substances Data)

Usage

Chemical structure

Contains an amino group, a phenoxy group, and a chloro group

Potential applications

Pharmaceutical and agrochemical industries

Potential biological activities

Antiviral, antibacterial, antiparasitic

Research focus

Synthesis and study of 2-amino-4-phenoxy-6-chloropyrimidine and its derivatives for development as a new therapeutic agent

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 108-95-2 phenol 
• 139-02-6 sodium phenoxide 
• 100-67-4 potassium phenolate 

Downstream Products

• 93871-78-4 2-amino-4,6-di(benzylamino)pyrimidine 
• 100763-47-1 N⁴-Benzyl-6-phenoxy-pyrimidine-2,4-diamine 
• 118644-50-1 N-(2,6-Dichlorbenzoyl)-N'-(4-chlor-6-phenoxypyrimidin-2-yl)harnstoff 

Relevant articles and documents

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation

We describe the discovery of three structurally differentiated potent and selective MTH1 inhibitors and their subsequent use to investigate MTH1 as an oncology target, culminating in target (in)validation. Tetrahydronaphthyridine 5 was rapidly identified as a highly potent MTH1 inhibitor (IC50 = 0.043 nM). Cocrystallization of 5 with MTH1 revealed the ligand in a φ-cis-N-(pyridin-2-yl)acetamide conformation enabling a key intramolecular hydrogen bond and polar interactions with residues Gly34 and Asp120. Modification of literature compound TH287 with O- and N-linked aryl and alkyl aryl substituents led to the discovery of potent pyrimidine-2,4,6-triamine 25 (IC50 = 0.49 nM). Triazolopyridine 32 emerged as a highly selective lead compound with a suitable in vitro profile and desirable pharmacokinetic properties in rat. Elucidation of the DNA damage response, cell viability, and intracellular concentrations of oxo-NTPs (oxidized nucleoside triphosphates) as a function of MTH1 knockdown and/or small molecule inhibition was studied. Based on our findings, we were unable to provide evidence to further pursue MTH1 as an oncology target.

Heterocyclic compounds as well as preparation method and application thereof

The invention belongs to the field of medicines and particularly relates to heterocyclic compounds with the structural characteristics shown in formula (I) or pharmaceutically acceptable salts, a preparation method and an application of the heterocyclic compounds as a nucleotide oxidative damage repairase MTH1 inhibitor. Pharmacological experiment results indicate that the compounds have significant inhabitation effects on the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

N-(2,6-Dihalobenzoyl)-N'-pyrimidinylureas

N-(2,6-Dichlorobenzoyl)- and N-(2,6-difluorobenzoyl)-N'-pyrimidinylureas 3b-3n have been synthesized by reaction of the corresponding aminopyrimidine derivatives with 2,6-dichlorobenzoyl isocyanate or 2,6-difluorobenzoyl isocyanate.The insecticial activit